Ipilimumab pharmacotherapy in patients with metastatic melanoma.

about

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse.

P2860

Q28536351-095A71C9-57E8-48E5-9320-3DE169C84578 Q38093572-3E0768B8-A22B-45E3-A40B-BA61B0ED3246

P2860

Ipilimumab pharmacotherapy in patients with metastatic melanoma.

Item

http://www.wikidata.org/entity/Q36161313

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Ipilimumab pharmacotherapy in patients with metastatic melanoma.

@ast

Ipilimumab pharmacotherapy in patients with metastatic melanoma.

@en

type

Item

label

Ipilimumab pharmacotherapy in patients with metastatic melanoma.

@ast

Ipilimumab pharmacotherapy in patients with metastatic melanoma.

@en

prefLabel

Ipilimumab pharmacotherapy in patients with metastatic melanoma.

@ast

Ipilimumab pharmacotherapy in patients with metastatic melanoma.

@en

P1476

Ipilimumab pharmacotherapy in patients with metastatic melanoma.

@en

P2093

Evan M Hersh

http://www.w3.org/2001/XMLSchema#string

Joanne M Jeter

http://www.w3.org/2001/XMLSchema#string

Lee D Cranmer

http://www.w3.org/2001/XMLSchema#string

P2860

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

CTLA-4 ligation blocks CD28-dependent T cell activation

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

CTLA-4 can function as a negative regulator of T cell activation

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Enhancement of antitumor immunity by CTLA-4 blockade

Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

P304

275-286

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/CMO.S7245

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22904648

http://www.w3.org/2001/XMLSchema#string

P921

Ipilimumaab

pharmacotherapy

P932

3418148

http://www.w3.org/2001/XMLSchema#string

Ipilimumab pharmacotherapy in patients with metastatic melanoma.

about

P2860

P2860

Ipilimumab pharmacotherapy in patients with metastatic melanoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932